Cell Therapeutics

www.ctibiopharma.com

Cell Therapeutics Reviews

5 Reviews
3.3
5 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
Cell Therapeutics President, CEO, and Director James A. Bianco
James A. Bianco
4 Ratings
  • 1 person found this helpful  

    Great Company - unfortunate luck

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Former Employee - Anonymous Employee in Seattle, WA
    Former Employee - Anonymous Employee in Seattle, WA

    I worked at Cell Therapeutics full-time

    Pros

    Excellent talent & people! Deep pipleline of potential products

    Cons

    Needs to catch a break

    Advice to ManagementAdvice

    Keep hiring top talent

    Recommends
    Positive Outlook
    Approves of CEO

Cell Therapeutics Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.ctibiopharma.com
Headquarters Seattle, WA
Size 50 to 149 Employees
Founded Unknown
Type Company - Public (CTIC)
Industry Biotech & Pharmaceuticals
Revenue $25 to $50 million (USD) per year

Cell Therapeutics (CTI) is a toxic avenger. The firm creates more effective and less toxic treatments for various forms of cancer. CTI is developing a number of cancer-fighting compounds, including pixantrone, a treatment for non-Hodgkin's lymphoma and other tumorous cancers, and Opaxio (paclitaxel poliglumex) for non-small cell lung and ovarian cancers. The company's Systems Medicine subsidiary is working on a potential sarcoma-fighter called brostallicin. CTI no longer markets any commercial products and instead focuses on research and development projects.

Work at Cell Therapeutics? Share Your Experiences

Cell Therapeutics

 
Click to Rate
or